PRIMA BIOMED REPORTS OVARIAN CANCER STUDY RESULTS

A A

Prima BioMed has reported favorable results in its ongoing Phase IIa clinical trial in ovarian cancer.

Trial data has indicated that 21 percent of patients had achieved either a clinical response to treatment or stabilization of their disease. Patients in the study are late-stage progressive ovarian cancer patients with no therapeutic alternative. Fifteen per cent of patients having achieved either a clinical response to treatment or stabilization of their disease in the trial's patient population, for whom standard therapies provide minimal benefit, is considered a benchmark response rate to demonstrate that a therapy has sufficient activity to warrant its progression to a comparative clinical trial.